Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS)
Rationale, Design, and Characteristics
Bibliographic Data
| ID | 15518655 |
|---|---|
| Authors | Scott R Clark (0000-0003-1640-5611, The University of Adelaide), K Oliver Schubert (0000-0003-1690-0209, The University of Adelaide), Andrew T Olagunju (0000-0003-1736-9886, The University of Adelaide), Ellen Lyrtzis (The University of Adelaide), Ellen Alexandra Lyrtzis, Bernhard T Baune (0000-0001-6548-426X, The University of Adelaide, corresponding author) |
| Year | 2018 |
| Volume | 9 |
| Pages | 662-662 |
| Publication date | 2018-12-03 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2018.00662 |
| PMID | 30559688 |
| OpenAlex | W2902860292 |
| Language | EN |
| References cited | 22 |
Prediction of treatment response and illness trajectory in psychotic disorders including schizophrenia, bipolar affective disorder, schizoaffective disorder, and psychotic depression is difficult due to heterogeneity in presentation and outcome. Consequently, patients may receive prolonged ineffective treatments leading to functional decline, illness chronicity, and iatrogenic physical illness. One approach to addressing these problems is to stratify patients based on historical, clinical, and biological signatures. Such an approach has the potential to improve categorization resulting in better understanding of underlying mechanisms and earlier evidence-based treatment with reduced side effect burden. To investigate these multimodal signatures we developed the Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS) employing a prospective study design and a healthy control group comparison. The main aim of this study is to investigate cognitive, and biological "genomics" markers of psychotic illnesses that can be integrated with clinical data to improve prediction of risk and define functional trajectories. We also aim to identify biological "genomic" signatures underpinning variation in treatment response and adverse medical outcomes. The study commenced in June 2016, including patients with primary diagnosis of psychotic disorders including schizophrenia, bipolar affective disorder, schizoaffective disorder, and psychotic depression according to DSM-5 criteria. The assessment covers a wide range of participant history (life stressors, trauma, and family history), cognitive dimensions (social perception, memory and learning, attention, executive function, and general cognition), measures to assess psychosocial function and quality of life, psychotic symptom severity, clinical course of illness, and parameters for adverse medical outcome. Blood is collected for comprehensive genomic discovery analyses of biological (genomic, transcriptomic, proteomic, and cell-biologic) markers. The CoFAPSS is a novel approach that integrates clinical, cognitive and biological "genomic" markers to clarify clinico-pathological basis of risk, functional trajectories, disease stratification, treatment response, and adverse medical outcome. The CoFAPSS team welcomes collaborations with both national and international investigators
Bipolar disorder · Cognition · Psychiatry · Psychosis · Psychosocial · Schizoaffective disorder · Schizophrenia (object-oriented programming · Bipolar Disorder and Treatment · Clinical Psychology · Medicine · Psychology · Schizophrenia research and treatment · Tryptophan and brain disorders
Working-memory capacity and the control of attention
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016
The Columbia–Suicide Severity Rating Scale
Machine Learning Approaches for Clinical Psychology and Psychiatry
Wgcna
Research Domain Criteria (RDoC)
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Global, regional, and national disability-adjusted life-years (Dalys) for 359 diseases and injuries and healthy life expectancy (Hale) for 195 countries and territories, 1990–2017
Specific impairments of planning
A Systematic Review of Mortality in Schizophrenia
Assessing the Performance of Prediction Models
Global, regional, and national disability-adjusted life-years (Dalys) for 333 diseases and injuries and healthy life expectancy (Hale) for 195 countries and territories, 1990–2016
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
Clinical, Functional, and Biological Correlates of Cognitive Dimensions in Major Depressive Disorder – Rationale, Design, and Characteristics of the Cognitive Function and Mood Study (CoFaM-Study)
Content validation of two SF-36 subscales for use in type 2 diabetes and non-dialysis chronic kidney disease-related anemia
Validation and calibration of the SF-36 health transition question against an external criterion of clinical change in health status
Assessment of differential item functioning in the Perceived Stress Scale-10
| Citation velocity | historical |
|---|---|
| Highly cited | No |